Clinical trials: Smoking, Tobacco
Tobacco Use
Expanding the Click City Tobacco Prevention Program to Include E-cigarettes and Other Novel Tobacco Products
The goal of this study is to modify a smoking prevention program for 5th and 6th grade students to also target vaping e-cigarettes.
- Trial name
- NCT03682900
- Testing
- Click City®: Tobacco, Usual Tobacco Curriculum
- Where
- United States
- Volunteers
- 2,673 people, healthy volunteers welcome
- Sponsor
- Oregon Research Behavioral Intervention Strategies, Inc.
Smoking Cessation
Cumulative Skin Irritation Potential of a New 15 mg Nicotine Patch
An investigation on the cumulative skin irritation potential of a newly developed 15 mg nicotine patch. Evaluation of skin irritation of a newly developed 15 mg nicotine transdermal patch.
- Trial name
- NCT00965913
- Testing
- Nicotine Patch, Nicotine Patch Comparator
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- McNeil AB
Substance Dependence
Relapse Prevention Study in Newly Abstinent Smokers
The purpose of this study is to determine the effect of GSK598809 as compared to placebo in preventing recently-quit smokers from going back to smoking.
- Trial name
- NCT00793468
- Testing
- GSK598809, Nicotine Replacement Transdermal Patch
- Where
- 10 sites in United States
- Sponsor
- GlaxoSmithKline
Nicotine Dependence, Nicotine Dependence, Cigarettes
Clinical Study Comparing 7 ENDS Products and 1 Combustible Cigarette Using 2 Delivery Methods.
A Randomized Study Comparing Nicotine Pharmacokinetics of Seven Electronic Cigarette Products and One Traditional Cigarette Across Two Delivery (10 puff and ad- libitum) Conditions, in Healthy Adult Smokers
- Conditions
- Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
- Trial name
- NCT03700112
- Testing
- JUUL Virginia Tobacco flavored 5.0% ENDS, PMI iQOS Heat sticks, Reynolds VUSE Solo ENDS - Original
- Where
- New Zealand
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Smoking Cessation
A Twelve-Week Study of Varenicline for Safety and Efficacy in Comparison With Placebo and Zyban for Smoking Cessation
The primary purpose of this study is to evaluate the safety and efficacy of varenicline given for a twelve week treatment period in comparison with placebo and Zyban for smoking cessation.
- Trial name
- NCT00141206
- Testing
- varenicline (CP-526,555)
- Where
- 20 sites in United States
- Volunteers
- 1,005 people
- Sponsor
- Pfizer
Drug Drug Interaction (DDI)
Drug-Drug Interaction (DDI) Study for TD-9855
This study is designed to assess the effect of fluvoxamine, itraconazole and smoking on the PK disposition of multiple doses TD-9855 in healthy male subjects.
- Trial name
- NCT03432793
- Testing
- TD-9855, Fluvoxamine, Itraconazole
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Smoking Cessation
Escape Smoke Project: Non-Intervention Non-Drug Multicenter Study on the Real-life Effectiveness of Smoking Cessation in General Practice in Denmark
Real life smoking cessation rates after 24 weeks non-intervention design. Approximately 40 General Practice (GP) centers with 800 smokers will participate.
- Trial name
- ESCAPE SMOKE (NCT01544621)
- Testing
- Smoking cessation
- Volunteers
- 544 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy, Non-Smoking
Evaluation of Varenicline Safety, Tolerability, Pharmacokinetics and Pro-Cognitive Effects in Healthy Elderly Non-Smoking Subjects
1. Characterize the tolerability and safety of repeated doses of varenicline in healthy non-smoking elderly subjects. 2. Describe the steady state pharmacokinetics of varenicline in healthy non-smoking elderly subjects. 3.
- Trial name
- NCT00694044
- Testing
- varenicline
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pfizer
Tobacco Dependence
Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment
To evaluate the safety, smoking cessation and reduction rate during 3 months of active nicotine replacement therapy (NRT) and a follow-up period of 3 months in smoking hospital physicians and staff who are motivated to quit
- Trial name
- NCT00749463
- Testing
- Nicotine Gum, Nicotine Patch
- Where
- 6 sites in China
- Volunteers
- 300 people
- Sponsor
- McNeil AB
Smoking Cessation
Comparison of Pharmacokinetic Profiles of 3 New Nicotine Gum Formulations With a Reference Gum
The purpose of the study is to compare the pharmacokinetic (PK) profiles and assess bioequivalence between three new nicotine gum formulations and a reference nicotine gum in healthy smokers.
- Trial name
- NCT02356913
- Testing
- Nicotine gum
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Fertin Pharma A/S
Healthy Smokers
Nicotine Patch - Bioequivalence Study
The purpose of this study is to evaluate the bioequivalence of a new transdermal nicotine patch to that of a reference formulation following repeated applications
- Trial name
- NCT02089308
- Testing
- Test treatment : V0116 transdermal patch, Reference treatment : Nicotine transdermal patch
- Where
- France
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Smoking, Smoking Behaviors
Abuse Liability of Two Modern Oral Nicotine Pouched Products
This is a single-site, open-label, randomized, 4-way cross-over study designed to evaluate elements of abuse liability (AL) including subjective effects and physiological measures (pharmacodynamics [PD]) and plasma nicotine…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT07595055
- Testing
- Usual Brand (UB) filtered, menthol or non-menthol combustible cigarette, Modern Oral Pouch Wintergreen-A 9 mg Nicotine, Modern Oral Pouch Wintergreen-B 9 mg Nicotine
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Electronic Cigarette Use
Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by ENDS Consumers
This study is being conducted to evaluate nicotine uptake, the potential abuse liability, and puffing topography associated with the use of an electronic nicotine delivery system (ENDS) with tobacco- and menthol-flavored…
- Trial name
- NCT04620616
- Testing
- RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, Subject Usual Brand ENDS
- Where
- 2 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Cheerain HK Limited
Stroke, Hypertension
DELPHI in Subjects at Risk for Stroke and Dementia
The DELPhi system is a software device that is used for the noninvasive evaluation of brain plasticity and connectivity. The DELPhi software uses EEG and TMS devices as accessories.
- Conditions
- Stroke, Hypertension, Diabete Mellitus, Dyslipidemias
- Trial name
- NCT03884647
- Testing
- DELPhI system
- Where
- 4 sites in United States, Israel
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- QuantalX Neuroscience
Smoking
Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 (THS 2.2)
The primary objective of this clinical study is to evaluate the pharmacokinetic (PK) profile (rate and amount of nicotine absorbed) following a single use of the THS 2.2 compared to the PK profiles from a single use of a…
- Trial name
- NCT01967732
- Testing
- THS 2.2, CC, NNS
- Where
- United Kingdom
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
A Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers
The primary objectives of this study are: To evaluate the pharmacokinetic (PK) parameters during repeat dosing of 1.5 mg or 3.0 mg cytisine when administered as the commercial 25-day schedule.
- Trial name
- NCT03303911
- Testing
- Cytisine
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Achieve Life Sciences
Nicotine Addiction, Drug Addiction
Clinical Trial of Smoking Cessation Mobile Phone Program
The Sponsor is doing a research study to assess the effects of a smartphone program designed to help users smoke less and eventually quit. When participants join, their involvement in the core study will last 8 weeks.
- Conditions
- Nicotine Addiction, Drug Addiction, Drug Dependence, Substance Use Disorder
- Trial name
- NCT02656745
- Testing
- Mobile Smoking Cessation Solution
- Where
- United States
- Volunteers
- 416 people
- Sponsor
- Click Therapeutics, Inc.
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Vaping, Underage
Human Factors Validation and Usability Testing of the IKE Age-Gating System
A multi-center human factors validation study to demonstrate the function of the IKE Bluetooth system on a chip (SoC) and mobile applications ability to age-gate a device, accurately identify an individuals age, race/ethnicity…
- Trial name
- NCT06952569
- Testing
- IKE System
- Where
- 4 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- IKE Tech
Nicotine Dependence, Nicotine Dependence, Cigarettes
United States Pre-Market Tobacco Application Pharmacokinetics
A Randomized, Open-Label, Cross-Over Study to Assess Nicotine Uptake and Subjective Measures with Use of JUUL 5% Electronic Nicotine Delivery Systems (ENDS) Compared to Usual Brand Combustible Cigarettes, a Comparator…
- Conditions
- Nicotine Dependence, Nicotine Dependence, Cigarettes, Tobacco Use, Tobacco Smoking
- Trial name
- US-PMTA-PK (NCT03719391)
- Testing
- Virginia Tobacco flavored JUUL 5% ENDS, Cool Mint flavored JUUL 5% ENDS, Mango flavored JUUL 5% ENDS
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.